ijms-logo

Journal Browser

Journal Browser

Anticancer Medicine and Cancer Immunotherapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1473

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
Interests: cancer

Special Issue Information

Dear Colleagues,

Anticancer medicine and cancer immunotherapy is a multifaceted topic focusing on the latest advancements and strategies in combating cancer. The scope of this topic encompasses the development and application of anticancer medicine, specifically designed to hinder the growth and spread of cancer cells. The scope includes chemotherapy agents, targeted therapies and hormonal treatments, each with distinct mechanisms of action and efficacy profiles. 

A significant part of the discussion revolves around cancer immunotherapy, an innovative treatment approach that harnesses the body's immune system to fight cancer. This segment would cover various types of immunotherapies, such as checkpoint inhibitors, CAR T-cell therapies and cancer vaccines, elucidating their roles in activating or enhancing the immune response against cancer cells.

The scope also entails an exploration of challenges and breakthroughs in these fields, including the issues of drug resistance, side effects and the development of personalized medicine strategies. The potential synergy between anticancer drugs and immunotherapy, aiming to enhance treatment effectiveness and patient outcomes, is a crucial aspect.

Furthermore, the topic would address the ongoing research and clinical trials that are paving the way for new treatments, alongside the ethical and economic considerations involved in the development and accessibility of these advanced therapies. The goal is to provide a comprehensive overview of the current landscape and future prospects of anticancer medicine and cancer immunotherapy, highlighting their pivotal roles in the evolving fight against cancer.

Prof. Dr. Chao-Liang Wu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer
  • cancer immunotherapy
  • CAR T-cell therapies
  • targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 2336 KiB  
Article
Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer
by Natsuko Sasajima, Makoto Sumazaki, Yoko Oshima, Masaaki Ito, Satoshi Yajima, Hirotaka Takizawa, Hao Wang, Shu-Yang Li, Bo-Shi Zhang, Yoichi Yoshida, Takaki Hiwasa and Hideaki Shimada
Int. J. Mol. Sci. 2024, 25(10), 5470; https://doi.org/10.3390/ijms25105470 - 17 May 2024
Viewed by 1246
Abstract
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer [...] Read more.
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer. Full article
(This article belongs to the Special Issue Anticancer Medicine and Cancer Immunotherapy)
Show Figures

Figure 1

Back to TopTop